針なし注射器市場の規模、シェア、トレンド、成長、予測(2026年~2034年)
市場概要
Fortune Business Insightsによると、世界の針なし注射器市場規模は2025年に1億1320万米ドルと評価され、2026年の1億3021万米ドルから2034年には4億400万米ドルに成長すると予測されており、2026年から2034年の予測期間中の年平均成長率(CAGR)は15.2%となる見込みです。北米は2025年に44.39%のシェアを占め、世界市場を牽引しました。痛みのない薬剤投与ソリューションへの需要の高まり、慢性疾患の蔓延、針刺し事故防止に関する意識の高まりが、市場拡大を後押ししています。
ニードルレス注射器は、従来の注射針を使用せず、皮膚の小さな開口部から高圧の液体を流し込むことで薬剤を投与する先進的な薬剤投与装置です。これらの装置は、注射針への不安軽減、患者の服薬遵守率向上、薬剤投与の簡便化、針刺し事故のリスク低減など、多くの利点を提供します。ワクチン接種プログラムや慢性疾患管理におけるニードルレス注射器の活用拡大は、世界のニードルレス注射器市場に新たな成長機会をもたらしています。
主要な市場推進要因
慢性疾患の蔓延拡大が市場成長を支える
糖尿病、骨粗鬆症、成長ホルモン欠乏症などの慢性疾患の罹患率の上昇は、針を使わない注射技術への需要を高める大きな要因となっている。慢性疾患を抱える患者は定期的な投薬を必要とすることが多く、そのため、簡便で痛みの少ない薬剤投与方法がますます重要になっている。
針を使わない注射器は、特に頻繁なインスリン投与が必要な患者にとって、従来の注射方法に代わる選択肢となります。これらの機器は、不快感や注射針に対する不安を軽減することで、治療の継続率を向上させることができます。したがって、慢性疾患の世界的な増加に伴い、これらの製品の普及が加速すると予想されます。
痛みのない薬剤投与ソリューションへの需要の高まり
患者の快適性や低侵襲医療技術への意識の高まりは、針を使わない注射器の普及を促進している。従来の注射は、特に子供や注射恐怖症の人にとって、不快感や不安を引き起こす可能性がある。
針を使わない注射システムは、高圧流体技術を用いて薬剤を投与することで、従来の注射針を不要にします。この方式は利便性を向上させ、様々な医療現場での薬剤投与をサポートします。
市場動向
針を使わない注射システムの技術的進歩
技術革新は、針を使わない注射器市場を形成する重要なトレンドです。メーカー各社は、薬剤投与と患者体験の向上を目指し、効率的で持ち運びやすく、使いやすい注射器の開発に注力しています。
注射機構、デバイス設計、投与精度における進歩は、これらのシステムの応用範囲拡大に貢献している。さらに、メーカー各社は、投与の利便性を高め、準備の手間を軽減する製品改良に注力している。
ワクチン接種プログラムの拡大
政府主導の予防接種イニシアチブの増加に伴い、針を使わない注射器メーカーにとって新たなビジネスチャンスが生まれている。これらの機器は、針刺し事故のリスクを軽減し、特定の予防接種手順を簡素化することで、大規模な予防接種プログラムを支援することができる。
ワクチン投与におけるこれらの技術の潜在的な応用は、製薬会社や研究機関が新しいワクチンや臨床試験のために針を使わない技術を評価することを促している。
無料サンプルをリクエストする: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/needle-free-injection-system-market-112405
市場の制約
針を使わない注射器の高コスト
針を使わない注射器は、従来の針を用いた注射システムに比べて価格が比較的高いため、市場における大きな制約となっている。機器価格の高さ、初期投資、維持費などが、特に発展途上国や予算に制約のある医療機関における普及を阻害する要因となっている。
The cost difference may discourage healthcare providers from transitioning to needle-free alternatives, despite their benefits in patient comfort and safety.
Regulatory Challenges and Limited Awareness
Stringent regulatory requirements can delay product approvals and commercialization. Manufacturers must demonstrate the safety, effectiveness, and reliability of their devices before introducing them into different markets.
Additionally, limited awareness regarding the benefits and applications of needle-free injectors in certain regions can restrict market penetration.
Needle Free Injectors Market Segmentation Analysis
The global needle free injectors market is segmented by type, application, delivery site, end-user, and geography. Increasing demand for convenient drug administration, improved patient safety, and advancements in injection technologies are influencing segmental growth.
By Type
Based on type, the market is divided into disposable and reusable injectors.
The disposable segment dominated the market in 2026 due to its convenience, ease of administration, and reduced risk of cross-contamination. These devices are particularly suitable for healthcare environments requiring quick medication delivery with minimal preparation.
The reusable segment is also expected to experience significant growth during the forecast period. Its durability, multiple-use capability, and potential cost-effectiveness are supporting adoption among healthcare providers.
By Application
Based on application, the market is categorized into autoimmune disorders, diabetes, pain management, and others.
The diabetes segment held the largest market share in 2026. The increasing prevalence of diabetes and the need for regular insulin administration are supporting demand for needle-free injection systems. These devices provide a less painful alternative to traditional injections and can improve patient adherence to treatment.
Meanwhile, the pain management segment is expected to register significant growth during the forecast period. Increasing surgical procedures and the need for effective post-operative pain management are contributing to the adoption of advanced drug delivery technologies.
By Delivery Site
Based on delivery site, the market is segmented into subcutaneous delivery, intradermal delivery, and intramuscular delivery.
The subcutaneous delivery segment dominated the market in 2026, supported by increasing applications in insulin and vaccine administration.
The intramuscular delivery segment is expected to grow significantly during the forecast period. Faster medication absorption and increasing use of these devices for hormone-based therapeutics are contributing to segment growth.
By End-user
Based on end-user, the market is divided into pharmaceutical and biotechnology companies and contract research and manufacturing organizations.
The pharmaceutical and biotechnology companies segment dominated the market in 2026. Increasing clinical research activities and the evaluation of needle-free systems for drug and vaccine administration are supporting its leading position.
The contract research and manufacturing organizations segment is also expected to record significant growth as clinical research organizations increasingly explore alternative drug delivery technologies.
Regional Analysis of the Needle Free Injectors Market
North America
North America dominated the global needle free injectors market with a 44.39% share in 2025. The regional market was valued at USD 50.27 million in 2025 and is projected to reach USD 57.82 million in 2026.
The region's growth is supported by increasing awareness of needle-free technologies, advanced healthcare infrastructure, and the presence of established manufacturers. The U.S. market is expected to witness considerable growth due to the strong presence of companies such as PharmaJet, Portal Instruments, and INOVIO Pharmaceuticals.
Europe
Europe represents another important regional market for needle-free injectors. The market was valued at USD 29.44 million in 2025 and is projected to reach USD 33.73 million in 2026.
Increasing collaborations and partnerships among medical device manufacturers are supporting regional market development. Companies are focusing on commercializing innovative injection systems to improve access to non-invasive drug delivery solutions.
Asia Pacific
Asia Pacific is expected to experience considerable growth during the forecast period. The regional market reached USD 23.59 million in 2025 and is projected to increase to USD 27.34 million in 2026.
Rapid improvements in healthcare infrastructure, expanding immunization programs, and increasing awareness of advanced drug delivery technologies are supporting regional growth. Countries such as China, India, and Japan are creating opportunities for manufacturers through growing healthcare investments and increasing demand for patient-friendly treatment options.
Latin America
The Latin American market is gradually expanding due to improvements in healthcare accessibility and increasing demand for advanced injection technologies. The region was valued at approximately USD 5.89 million in 2025 and is expected to reach USD 6.74 million in 2026.
Growing vaccination requirements and increasing awareness regarding needle-stick injury prevention are expected to support product adoption.
Middle East & Africa
The Middle East & Africa market is expected to witness steady growth during the forecast period. The regional market was valued at USD 4.03 million in 2025 and is projected to reach USD 4.59 million in 2026.
Increasing healthcare investments, improvements in medical infrastructure, and rising demand for vaccination services are supporting the adoption of needle-free injection technologies.
Competitive Landscape of the Needle Free Injectors Market
The global needle free injectors market comprises several established medical device manufacturers focusing on product innovation, strategic partnerships, clinical research, and commercialization activities. Companies are investing in advanced injection technologies to strengthen their competitive positions and expand their geographical presence.
The increasing emphasis on painless drug delivery and vaccination applications is encouraging manufacturers to develop more efficient and user-friendly devices.
Key Companies Operating in the Needle Free Injectors Market
The major companies profiled in the market include:
- PharmaJet – U.S.
- CROSSJECT – France
- Portal Instruments – U.S.
- NuGen Medical Devices – Canada
- INOVIO Pharmaceuticals – U.S.
- Ferring – Switzerland
- Aijex Pharma International Inc. – Japan
- IntegriMedical – U.S.
Recent Industry Developments
- March 2025: PharmaJet announced that its Tropis intradermal delivery system was used in the World Health Organization's polio eradication campaign conducted in Pakistan in February 2025.
- February 2025: PharmaJet shared the latest immunization study results at the 61st Annual Medical Conference and International Health Exhibition.
- May 2024: Serum Institute of India announced a strategic investment in IntegriMedical by acquiring a 20% stake in the company to advance needle-free injection system technology.
- October 2024: PharmaJet announced positive results from a study in Nigeria evaluating its Tropis ID system for intradermal fractional inactivated poliovirus vaccine administration.
Future Opportunities in the Needle Free Injectors Market
Growing Clinical Research and Vaccine Development Activities
Increasing clinical research activities focused on developing new drugs and vaccines are expected to create lucrative opportunities for the needle free injectors market. Pharmaceutical and biotechnology companies are exploring needle-free technologies to improve medication delivery and enhance patient acceptance.
For instance, in December 2024, PharmaJet announced the publication of a Phase 1 clinical trial evaluating the safety and immunogenicity of plasmid DNA Hantavirus vaccines administered using its Stratis IM needle-free system.
The growing use of these devices in clinical research and vaccine development is expected to support market expansion through 2034.
Read Report Insights: https://www.fortunebusinessinsights.com/needle-free-injection-system-market-112405
Conclusion
The global needle free injectors market is expected to experience strong growth through 2034, supported by the increasing prevalence of chronic diseases, rising demand for painless drug delivery, and expanding vaccination programs. Technological advancements and growing clinical research activities are creating additional opportunities for manufacturers.
北米は引き続き市場をリードする地位を維持すると予想される一方、アジア太平洋地域は医療インフラの改善と非侵襲的医療技術の普及拡大により、有望な成長機会を提供すると見込まれています。さらに、戦略的パートナーシップ、製品イノベーション、高度な注射システムへの投資は、競争環境を強化する可能性が高いでしょう。世界の市場規模は2034年までに4億400万米ドルに達すると予測されており、針を使わない注射技術は現代医療においてますます重要な役割を果たすと予想されます。
よくある質問(FAQ)
- 世界の針なし注射器市場の規模はどれくらいですか?
世界の針なし注射器市場は、2025年には1億1320万米ドルと評価されました。2026年の1億3021万米ドルから、2034年には4億400万米ドルに成長すると予測されています。
- 針なし注射器市場の予想CAGR(年平均成長率)はどのくらいですか?
市場は、2026年から2034年の予測期間中に年平均成長率(CAGR)15.2%を記録すると予想されている。
- 針なし注射器市場において、どのセグメントが支配的な地位を占めているのか?
2026年には、タイプ別に見ると使い捨て製品が市場を席巻し、用途別に見ると、定期的かつ簡便なインスリン投与へのニーズの高まりから、糖尿病が最大のシェアを占めた。
- 針なし注射器市場において、どの地域が支配的な地位を占めていますか?
北米は、高度な医療インフラ、意識の高まり、そして主要メーカーの存在に支えられ、2025年には世界市場の44.39%を占め、市場を席巻した。
- 針を使わない注射器市場における主要プレーヤーは誰ですか?
この市場で事業を展開している主要企業には、PharmaJet、CROSSJECT、Portal Instruments、NuGen Medical Devices、INOVIO Pharmaceuticals、Ferring、Aijex Pharma International Inc.、およびIntegriMedicalなどがある。
日本の市場を牽引する要因とは?最新の針なし注射器市場に関する洞察をご覧ください。